or Topieal therapy has long played a significant role in treatin g ear disease. Ototopical agents offer a variety of advantages, the most significa nt being the ir ability to con centrate medication in the ear. Fo r exa mple, the two currently availabl e flu oroquinolone drop s--ciproflo xacin/ dex amethasone and ofloxacin otic-ca n del iver a concentration of 3,000 ug/ml, which far exceeds the tissue concentration delivered to the middle ear via sys temic adm inist ration and far exceed s the minimum inhibitory concentration for tre atin g kno wn ear patho gen s.
Increasing awareness of ototoxic ity
It ha s long been known that the aminog lycoside antibio tics have ototoxic and nephrotoxic pot enti al when gi ven systemically. Th is finding first came to light shortly after the discovery of streptomycin was reported in 1944. ' Neomycin and gentamiein were subse quently develop ed in the hope s that they could be useful as less toxic alternatives, but such did not prov e to be the case. Multiple animal studies have show n that topi cally appl ied aminoglycosides can be ototoxic.>' Still, for many years otolary ngolog ists were not completely aware of the true clinical incidenee of ototo xicity from topieal aminoglycosides. In 199 3, Lundy and Gr aham published their nationwide survey of 2,235 otolaryn golo gist s.' Th ey reported that 94% of res pondents used ototopicals in the presence of post-t ympanostom y tube otorrhea, 84% used them in the pre sence of a drain ing perforation , and 75 % used them with intr aop erative pac k-ingoYet, despite such widespread use in infla med ears, onl y 3.4 % of the respondents repor ted that they had witne ssed irreversible inner ear damage that had been unequivocably caused by an ototopical dru g.
A year late r, Roland published an analys is of report s in theAmeric an and European literature (including the Lund y and Gr aham survey) and caleulated the reported ineidence of top ieal aminoglyco side toxicit y." Even with the 12 • Volume 83 • Suppl 1 bro adest possibl e criteria for defin ing ototox icity , the incidenee of ototox icity was determ ined to be approximatel y onl y 1 in 10,000 .
Of note, the pr imary indica tor of ototoxicity in many of these ea rlier studies was he aring loss; ves tib ular symptom s and other complica tions were often not taken into acco unt because they were either unrecogn ized or unrepo rted (unilateraI compe nsa tion might ex plain the fa ilure to recognize ves tibulotoxicity).
During the past decade, we have come to leam more about the true incidene e and nature of ototoxicity, It is not a co inc idence that the initi al conce m for ototoxicity with regard to aminog lycos ide-containing eardro ps arose in Canada. Th e mos t wide ly pres cribed eardro p there is gen tamicin/hydrocortiso ne . It is weIl known tha t gentami cin ca uses a grea ter deg ree of vesti bulotoxicity than coc hleotox icity. Otolaryngologists in Can ada began reporting ves tibular complai nts in patients who were using am inog lycoside-co ntai ning dro ps as ea rly as 1994 . 7 -10 Th ese compl aints included di zziness, dysequ ilibrium, and eve n ataxia in some cases. Bath et al published the largest series ever repor ted of patients (n =29) wit h true, unmi tigated ototoxic ity caused by commercially available aminog lycoside-con tai ning drops applied topically to the ear. ? Of interest was the fact that the ave rage du rati on of aminog lycoside use in that series was 16 days. A number of those patient s, in fac t, had used these drops for several month s. In this gro up, 9 patients developed ataxia, 7 never retume d to wo rk, and 5 were con fined to a whee lehair.
These reports led Health Ca nada to issue wami ngs regardin g the potenti al ototox ic effects of aminoglycoside eardro ps and to reco mmend that aminoglycos ide drops sho uld not be used in an open infec ted ear for more than 7 days.' :" A longer duration of thera py in these patients might play a significa nt ro le in ca using ototoxicity. It is suspec ted that as the infection clears with therapy, the round window becom es more perm eable in the nownor mal middl e ear space, whic h increases the ototoxic potent ial of continued app lica tio n of aminoglycoside drop s.
"Therapeutic toxicity"
As long ago as 1957 , Sc huknec ht used intratympan ic streptomycin for vestibular ablation in patients with Meniere's disease." Since then, others have reported success with the use of transtympanic gentamicin to ablate vestibular function in Meniere 's patients.P'" Gentamicin is the preferred aminoglycoside for transtympanic vestibular ablation because it is more vestibulotoxic than cochleotoxic and therefore it may ablate vestibular function while preserving hearing.
The findings on inadvertent ototoxicity from ototopical agents led researchers to conduct an interesting study of intentional vestibular ablation for therapeutic purposes using commercially prepared ototopical agents. Kaplan et al used the commercial gentamicin/betamethasone preparation to treat 20 patients with incapacitating Meniere 's disease." They inserted a ventilation tube into the ear of each patient and instructed each to instill 3 drops four times a day until they began to experience dizziness. Most patients experienced ototoxicity by day 12, and half of them exhibited no response to ice-water calorics. None of the 20 patients experienced any hearing loss.
An important point to keep in mind is that these patients already had an existing vestibular deficit secondary to Meniere 's disease, and they did not have evidence of chronic ear disease. But this study elearly proved two points: (1) that ototopical drops will enter the middle ear space through a tympanostomy tube (a fact that has been doubted by some physicians) and (2) that commercially available aminoglycoside eardrops elearly have ototoxic potential.
Other ototopical agents
Many antibiotics or antiseptic agents used in ototopical therapy have been implicated as having ototoxic potential when tested in animais, ineluding gentian violet, acetic acid, ethanol, and chlorhexidine, among others. 2 ,15-17 Interestingly, there is no evidence that the off-label use of topieal antifungal agents (e.g., miconazole, elotrimazole, tolnaftate, and nystatin) is ototoxic." It is well known that the differences in cochlear anatomy and physiology among species makes extrapolation to humans difficult at best.
The introduction of the quinolone otic drops in 1998 launched a newera in ototopical therapy. Clinical trials of the quinolones in adults and children have shown no evidence of ototoxicity.":" Nor have animal studies implicated quinolone drops as being ototoxic.v'
Quinolone-containing eardrops are not only safe, but they also are highly effective against known ear pathogens,21-23Quinolones in general have a broader spectrum of activity than aminoglycosides, and they are highly effective against Pseudomonas spp, and other ear pathogens, especially at the middle ear concentrations that can be achieved with topieal therapy.
The safety profile of the quinolones is all the more consequential in light of data indicating that some patients are highly susceptible to aminoglycoside toxicity as a result of an inherited mitochondrial gene abnormality." Patients with such a mutation-it is most common in Asian and Middle Eastern populations-can experience significant hearing loss after exposure to relatively small amounts of systemic aminoglycosides. Genetic susceptibility to topically applied aminoglycosides is unknown.
Medicolegal issues
Another ongoing development that has led us to readdress the issue of ototoxicity is the ever-increasing amount of malpractice litigation in the United States and Canada. It has been difficult to accurately ascertain exactly how many of these cases exist. It is known that in some cases of suspected ototoxicity, there was no evidence ofhearing loss; vestibularcomplaints were the primary issue in these patients, These kinds of cases have led to an increased awareness of the potential for ototoxicity of aminoglycoside-containing eardrops.
Summary
As we continue to learn more about ototoxicity from ototopical drugs, there are several key points we must keep in mind:
• Aminoglycoside antibiotics used in ototopical agents do have ototoxic potential.
• Reported cases of ototoxicity are relatively uncommon, but the potential for serious complications does exist.
• Subelinical unilateral vestibular deficits do go unrecognized.
• Superior alternatives to aminoglycoside drops, particularly the quinolone drops, are readily available.
• The quinolones are superior to the aminoglycosides in terms of safety, bacterial eradication, and elinical cure and are therefore the drops of choice for treating otorrhea in an open infected ear.
